Aurigene to Present its Programs on Covalent, Selective CDK7 Inhibitors, Novel Peptide Antagonists of CD47-SIRPa Interaction and Inhibitors of MALT-1 Signalling at the AACR 2017

Friday, March 31, 2017 General News
Email Print This Page Comment
Font : A-A+

BANGALORE, March 31, 2017 /PRNewswire/ --

Aurigene will present data for its:

  1. Proprietary
    novel, first-in-class, peptide antagonists of CD47-SIRPα interaction program which is currently in late lead optimization stage,
  2. Preclinical stage covalent, highly selective CDK7 inhibitors program and
  3. Selective, covalent inhibitors
    of MALT-1 signalling program.

(Logo: http://photos.prnewswire.com/prnh/20130418/608115 )

Additional information on the presentations can be found below and abstracts can be accessed at http://www.aacr.org.

Poster Presentations

Peptide antagonists targeting CD47- SIRPα

- Title: Targeting CD47- SIRPα interaction by novel peptide-based antagonists

- Session Category: Immunology

- Session Title: Tumor Microenvironment and Checkpoints

- Session Date and Time: Monday Apr 3, 2017 8:00 AM - 12:00 PM

- Location: Convention Center, Halls A-C, Poster Section 27

- Poster Board Number: 28

- Permanent Abstract Number: 1650

Covalent, selective, CDK7 inhibitors

- Title: Identification of a novel preclinical candidate for CDK7 inhibition

- Session Title: Late-Breaking Research: Mol Cell Biology 4

- Session Date and Time: Wednesday Apr 5, 2017 8:00 AM - 12:00 PM

- Session Location: Poster Section 36

- Poster Board Number: 3

- Permanent Abstract Number: LB-317

Covalent, MALT-1 Inhibitors

- Title: Potent small molecule compounds that selectively inhibit proliferation of ABC-DLBCL cell lines

- Session Category: Experimental and Molecular Therapeutics

- Session Title: Novel Chemotherapies

- Session Date and Time: Wednesday Apr 5, 2017 8:00- 12:00 PM

- Location: Convention Center, Halls A-C, Poster Section 4

- Poster Board Number: 10

- Permanent Abstract Number: 5108

About Aurigene

Aurigene is a specialized biotechnology company, engaged in discovery and early clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene is focused on oral check-point inhibitors, precision-oncology and the Th-17 pathway. Aurigene's oral PD-L1/ VISTA antagonist program is currently in Phase 1 clinical development with its partner. Aurigene has partnered with several large- and mid-pharma companies in the United States and Europe and has delivered over 15 compounds which are in clinical development.

For more information, please visit Aurigene's website at: http://aurigene.com/.

Media Contact: Rajshree KT Director Strategic Alliances +91-40-4465-7777

SOURCE Aurigene Discovery Technologies Limited



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook